2. Search Result
Search Result
Results for "

L-DOPA

" in MCE Product Catalog:

24

Inhibitors & Agonists

3

Peptides

6

Natural
Products

8

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-N0304
    L-DOPA

    LevoDOPA; 3,4-Dihydroxyphenylalanine

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease.
  • HY-N0304A
    L-DOPA sodium

    LevoDOPA sodium; 3,4-Dihydroxyphenylalanine sodium

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research.
  • HY-116016
    Etilevodopa

    L-DOPA ethyl ester; LevoDOPA ethyl ester

    		 Dopamine Receptor Drug Metabolite Neurological Disease
    Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine.
  • HY-116016A
    Etilevodopa hydrochloride

    L-DOPA ethyl ester hydrochloride; LevoDOPA ethyl ester hydrochloride

    		 Dopamine Receptor Drug Metabolite Neurological Disease
    Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine.
  • HY-N0304S2
    L-DOPA-13C

    		Dopamine Receptor Endogenous Metabolite
    L-DOPA- 13C is the 13C labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].
  • HY-132392S
    L-DOPA-2,5,6-d3

    		Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA-2,5,6-d3 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain[1][2][3].
  • HY-N0304S
    L-DOPA-d6

    LevoDOPA-d6; 3,4-Dihydroxyphenylalanine-d6

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA-d6 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].
  • HY-N0304S1
    L-DOPA-d6-1

    LevoDOPA-d6-1; 3,4-Dihydroxyphenylalanine-d6-1

    		 Dopamine Receptor Endogenous Metabolite
    L-DOPA-d6-1 is the deuterium labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].
  • HY-141647
    [18F]-Labeled L-dopa precursor

    		Dopamine Receptor Others
    [18F]-Labeled L-dopa precursor is a precursor for synthesis of 18F-labeled L-dopa extracted from patent WO2014095739A1, example 8.
  • HY-113468A
    3-O-Methyldopa

    3-Methoxy-L-tyrosine; 3-O-Methyl-L-DOPA

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease
    3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine.
  • HY-113468AS
    3-O-Methyldopa-d3

    3-Methoxy-L-tyrosine-d3; 3-O-Methyl-L-DOPA-d3

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease
    3-O-Methyldopa-d3 is deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine[1].
  • HY-113468AS1
    3-O-Methyldopa-d3 hydrate

    3-Methoxy-L-tyrosine-d3 (hydrate); 3-O-Methyl-L-DOPA-d3 (hydrate)

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease
    3-O-Methyldopa-d3 (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine[1].
  • HY-116750
    6-Hydroxykaempferol

    		Others Others
    6-Hydroxykaempferol, a flavonoid, is a competitive tyrosinase inhibitor with an IC50 value of 124 μM. 6-Hydroxykaempferol has a Ki value of 148 μM relative to L-DOPA as a substrate and effectively inhibits the activity of the enzyme by binding to the active site of the enzyme.
  • HY-N10950
    Vanicoside E

    		Dopamine Receptor Cancer
    Vanicoside E is an antioxidant and antitumor agent. Vanicoside E inhibits L-Tyrosine (HY-N0473) and L-DOPA (HY-N0304) with IC50s of 45.23 μM and 189.96 μM, respectively.
  • HY-149207
    Tyrosinase-IN-11

    		Tyrosinase Metabolic Disease
    Tyrosinase-IN-11 is a potent tyrosinase inhibitor with IC50s of 50 nM and 64 nM for L-tyrosinase and L-dopa, respectively. Tyrosinase-IN-11 has significant antioxidant activity and low cytotoxicity. Tyrosinase-IN-11 has the potential for skin hyperpigmentation research.
  • HY-15257
    Mavoglurant

    AFQ056

    		 mGluR Neurological Disease
    Mavoglurant (AFQ056) is a potent, selective, non-competitive and orally active mGluR5 antagonist, with an IC50 of 30 nM. Mavoglurant shows a >300 fold selectivity for the mGluR5 over all targets (238) tested. Mavoglurant can be used for the research of Fragile X syndrome (FXS), and L-dopa induced dyskinesias in Parkinson's disease.
  • HY-W152604
    Cyclo(glycyl-L-leucyl)

    Cyclo(leu-gly)

    		 Dopamine Receptor Neurological Disease
    Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias.
  • HY-W401531S
    (R)-3-O-Methyldopa-d3

    		Dopamine Receptor Endogenous Metabolite Neurological Disease
    (R)-3-O-Methyldopa-d3 is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].
  • HY-W401531S1
    (R)-3-O-Methyldopa-d3 hydrochloride

    		Dopamine Receptor Endogenous Metabolite Neurological Disease
    (R)-3-O-Methyldopa-d3 (hydrochloride) is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].
  • HY-106405
    Nebicapone

    BIA 3-202

    		 COMT Metabolic Disease
    Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease.
  • HY-N3237
    Mulberrofuran H

    		Dopamine Receptor Inflammation/Immunology
    Mulberrofuran H is a 2-arylbenzofuran derivative from the cultivated mulberry tree (Morus lhou (ser.) Koidz.). Mulberrofuran H demonstrates potent inhibition against substrates L-tyrosine (IC50=4.45 µM) and L-DOPA (IC50=19.70 µM). Mulberrofuran H also shows potent anti-inflammatory and antioxidative activities.
  • HY-P1335
    CTAP

    		Opioid Receptor Neurological Disease
    CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction.
  • HY-N2278
    Kushenol A

    Leachianone E

    		 Tyrosinase Glucosidase Cancer
    Kushenol A (Leachianone E) is isolated from the root of Sophora flavescent. Kushenol A is a non-competitive tyrosinase inhibitor to block the conversion of L-tyrosine to L-DOPA, shows IC50 and Kivalues of 1.1 μM and 0.4 μM, respectively. Kushenol A is a flavonoid antioxidant, has inhibitory effects on alpha-glucosidase (IC50: 45 μM; Ki: 6.8 μM) and β-amylase. Kushenol A is confirmed as potential inhibitors of enzymes targeted by cosmetics for skin whitening and aging.
  • HY-P1335A
    CTAP TFA

    		Opioid Receptor Neurological Disease
    CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction.